Monoclonal Antibody vs Small Molecule — Rare Disease Deal Terms Comparison
Market Analysis
In rare disease, Monoclonal Antibody and Small Molecule represent two of the most actively transacted modalities. At Phase 2, Monoclonal Antibody deals carry a median total deal value of $2.2B with $409M upfront, compared to $2.4B total value and $446M upfront for Small Molecule. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Monoclonal Antibody development milestones average $395M versus $431M for Small Molecule. Commercial milestones are $951M for Monoclonal Antibody and $1.0B for Small Molecule. Royalty rates range from 7.9%-15.9% for Monoclonal Antibody and 7.9%-15.7% for Small Molecule.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Monoclonal Antibody and Small Molecule deal terms compare in rare disease?
Which modality commands higher royalty rates: Monoclonal Antibody or Small Molecule?
How do milestone structures differ between Monoclonal Antibody and Small Molecule?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.